The Long-HER study: clinical and molecular analysis of patients with HER2+ advanced breast cancer who become long-term survivors with trastuzumab-based therapy.
<h4>Background</h4>Trastuzumab improves survival outcomes in patients with HER2+ metastatic breast cancer. The Long-Her study was designed to identify clinical and molecular markers that could differentiate long-term survivors from patients having early progression after trastuzumab trea...
Guardado en:
Autores principales: | Angelo Gámez-Pozo, Ramón M Pérez Carrión, Luis Manso, Carmen Crespo, Cesar Mendiola, Rocío López-Vacas, Julia Berges-Soria, Isabel Álvarez López, Mireia Margeli, Juan L Bayo Calero, Xavier González Farre, Ana Santaballa, Eva M Ciruelos, Ruth Afonso, Juan Lao, Gustavo Catalán, José V Álvarez Gallego, José Miramón López, Francisco J Salvador Bofill, Manuel Ruiz Borrego, Enrique Espinosa, Juan A Fresno Vara, Pilar Zamora |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Public Library of Science (PLoS)
2014
|
Materias: | |
Acceso en línea: | https://doaj.org/article/96570f731e5b47eda63fe7f906eaa872 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Role of trastuzumab emtansine in the treatment of HER2-positive breast cancer
por: Oostra DR, et al.
Publicado: (2014) -
Neratinib plus trastuzumab is superior to pertuzumab plus trastuzumab in HER2-positive breast cancer xenograft models
por: Jamunarani Veeraraghavan, et al.
Publicado: (2021) -
Trastuzumab emtansine in the treatment of HER2-positive metastatic breast cancer in Japanese patients
por: Sawaki M
Publicado: (2014) -
Phenotypic changes of HER2-positive breast cancer during and after dual HER2 blockade
por: Fara Brasó-Maristany, et al.
Publicado: (2020) -
An integrated stress response via PKR suppresses HER2+ cancers and improves trastuzumab therapy
por: Cedric Darini, et al.
Publicado: (2019)